Loading
Genocury Biotech
Genocury Biotech, in Shenzhen, is testing CAR-T treatments made inside the patient's body from a single infusion, rather than in a laboratory, for lymphoma, leukaemia and myeloma. The trials are early and run by hospital investigators in China.
Also called: Shenzhen Genocury Biotech Co., Ltd.济因生物Genocury
Overview
Shenzhen Genocury Biotech develops in vivo CAR-T therapies: an intravenous product that generates CAR-T cells inside the body. On ClinicalTrials.gov it sponsors investigator-initiated, single-centre studies of JY231 in relapsed or refractory B-cell lymphoma and leukaemia (NCT06678282, started 2023; NCT06890065, started 2025) and of JY232 in relapsed or refractory multiple myeloma (NCT07336823, registered January 2026). In April 2025 the company reported a single case from an investigator-initiated trial at Tongji Hospital: a patient with relapsed or refractory diffuse large B-cell lymphoma reached complete remission within 28 days of one dose of its in vivo CD19 CAR-T, given without lymphodepleting chemotherapy, with no cytokine release syndrome or ICANS reported. That is one patient. OrbiMed's portfolio page describes the company as developing in vivo CAR-T for oncology and autoimmune diseases. Its website also lists iPSC and reporter cell-line services.
Headquarters
Shenzhen, CN
Scorecard
All companies#681of 1706 companies, score 4
- phase 1/2 +2
- modalities +2
0 approved, 0 in phase 3, 2 earlier, 0 targets, 0 registry studies. Formula on the scorecards page.
Funding
All startupsStartup
Investors
Type
Stage
Startup
Website
Products
2Phase 1In vivo CAR-T (an infusion that makes CAR-T cells inside the body)
JY231 is an experimental in vivo CAR-T therapy from Genocury Biotech, in early studies for B-cell non-Hodgkin lymphoma and B-cell acute lymphoblastic leukaemia.
Phase 1In vivo CAR-T (an infusion that makes CAR-T cells inside the body)
JY232 is an experimental in vivo CAR-T therapy from Genocury Biotech, in early studies for multiple myeloma.
Notes
- Founding year not stated on a source read.
- The April 2025 release does not name the product; whether JY231 is the CD19 product described is not stated, so the CD19 target is from the release and not from the registry.
- The website's pipeline page loads from an API and could not be read as text; HQ is the Shenzhen address in the site footer.
- None of the three Genocury trials has an OnCo trial record. ClinicalTrials.gov lists phase 'not applicable' for the JY231 studies and early phase 1 for JY232.
Connected
15Similar pages
- PersonMichel Sadelain
Shares In vivo CAR-T, CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia.
- CompanyVivacta Bio
Shares OrbiMed, In vivo CAR-T, CD19.
- CompanyFamiCordTx
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma.
- CompanyImugene
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma.
- CompanyCellogen Therapeutics
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma.
- CompanyStarna Therapeutics
Shares In vivo CAR-T, CD19, Non-Hodgkin lymphoma (all types).
- PersonZelig Eshhar
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia, Multiple myeloma.
- CompanyUmoja Biopharma
Shares In vivo CAR-T, CD19, Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma.
cancers
fronts
technologies
targets
drugs
companies
trials
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
1stoncology.com · 1
ClinicalTrials.gov · 1
genocury.com · 1
orbimed.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/